Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James W Murrough

Showing results (11-20 of 173) with videos related to

Pageof 18
Sort By:
Current Psychiatry Reports|September 22, 2012
Is there anything really novel on the antidepressant horizon?James W Murrough, Dennis S Charney
Current Treatment Options in Psychiatry|February 27, 2016
"Does Ketamine Have Rapid Anti-Suicidal Ideation Effects?"Laili Soleimani, Alison Welch, James W Murrough
The Psychiatric Clinics of North America|May 6, 2023
Brain Features of Treatment-Resistant Depression: A Review of Structural and Functional Connectivity Magnetic Resonance Imaging StudiesMora M Grehl, Sara Hameed, James W Murrough
Frontiers in Psychiatry|April 5, 2021
Editorial: Pharmacotherapy of Anxiety Disorders: Promises and PitfallsAmir Garakani, Rafael C Freire, James W Murrough
Brain and Behavior|December 15, 2020
Intrasubject functional connectivity related to self-generated thoughtsDaniel Brennan, James W Murrough, Laurel S Morris
Evidence-Based Mental Health|April 8, 2016
Ketamine for treatment-resistant depression: recent developments and clinical applicationsJaclyn Schwartz, James W Murrough, Dan V Iosifescu
CNS Drugs|March 8, 2022
The Potential of KCNQ Potassium Channel Openers as Novel AntidepressantsSara Costi, Ming-Hu Han, James W Murrough
Neuropsychiatric Disease and Treatment|August 27, 2013
Novel glutamatergic drugs for the treatment of mood disordersKyle Ab Lapidus, Laili Soleimani, James W Murrough
Neuroscience Letters|December 4, 2016
Neuropeptide Y, resilience, and PTSD therapeuticsMarin Kautz, Dennis S Charney, James W Murrough
Pharmaceuticals (Basel, Switzerland)|June 10, 2020
Pharmacological Treatments for Patients with Treatment-Resistant DepressionValerie L Ruberto, Manish K Jha, James W Murrough
Pageof 18

Showing results (11-20 of 173) with videos related to

Sort By:
Pageof 18
Current Psychiatry Reports|September 22, 2012
Is there anything really novel on the antidepressant horizon?James W Murrough, Dennis S Charney
Current Treatment Options in Psychiatry|February 27, 2016
"Does Ketamine Have Rapid Anti-Suicidal Ideation Effects?"Laili Soleimani, Alison Welch, James W Murrough
The Psychiatric Clinics of North America|May 6, 2023
Brain Features of Treatment-Resistant Depression: A Review of Structural and Functional Connectivity Magnetic Resonance Imaging StudiesMora M Grehl, Sara Hameed, James W Murrough
Frontiers in Psychiatry|April 5, 2021
Editorial: Pharmacotherapy of Anxiety Disorders: Promises and PitfallsAmir Garakani, Rafael C Freire, James W Murrough
Brain and Behavior|December 15, 2020
Intrasubject functional connectivity related to self-generated thoughtsDaniel Brennan, James W Murrough, Laurel S Morris
Evidence-Based Mental Health|April 8, 2016
Ketamine for treatment-resistant depression: recent developments and clinical applicationsJaclyn Schwartz, James W Murrough, Dan V Iosifescu
CNS Drugs|March 8, 2022
The Potential of KCNQ Potassium Channel Openers as Novel AntidepressantsSara Costi, Ming-Hu Han, James W Murrough
Neuropsychiatric Disease and Treatment|August 27, 2013
Novel glutamatergic drugs for the treatment of mood disordersKyle Ab Lapidus, Laili Soleimani, James W Murrough
Neuroscience Letters|December 4, 2016
Neuropeptide Y, resilience, and PTSD therapeuticsMarin Kautz, Dennis S Charney, James W Murrough
Pharmaceuticals (Basel, Switzerland)|June 10, 2020
Pharmacological Treatments for Patients with Treatment-Resistant DepressionValerie L Ruberto, Manish K Jha, James W Murrough
Pageof 18